Exposure to repeated immobilization stress inhibits cocaine-induced increase in dopamine extracellular levels in the rat ventral tegmental area

Pharmacological Research : the Official Journal of the Italian Pharmacological Society
Ramón Sotomayor-ZárateKatia Gysling

Abstract

A higher vulnerability to drug abuse has been observed in human studies of individuals exposed to chronic or persistent stress, as well as in animal models of drug abuse. Here, we explored the effect of repeated immobilization stress on cocaine-induced increase in dopamine extracellular levels in VTA and its regulation by corticotropin-releasing factor (CRF) and GABA systems. Cocaine (10mg/Kg i.p.) induced an increase of VTA DA extracellular levels in control rats. However, this effect was not observed in repeated stress rats. Considering the evidence relating stress with CRF, we decided to perfuse CRF and CP-154526 (selective antagonist of CRF1 receptor) in the VTA of control and repeated stress rats, respectively. We observed that perfusion of 20μM CRF inhibited the increase of VTA DA extracellular levels induced by cocaine in control rats. Interestingly, we observed that in the presence of 10μM CP-154526, cocaine induced a significant increase of VTA DA extracellular levels in repeated stress rats. Regarding the role of VTA GABA neurotransmission, cocaine administration induced a significant increase in VTA GABA extracellular levels only in repeated stress rats. Consistently, cocaine was able to increase VTA DA extracellular...Continue Reading

References

Oct 22, 1990·Brain Research·J G PfausH C Fibiger
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·G Di Chiara, A Imperato
Oct 24, 1983·Brain Research·K Gysling, R Y Wang
Nov 25, 1993·Nature·D L Cameron, J T Williams
Jan 18, 2002·Psychopharmacology·R Sinha
Jun 3, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Bin WangZhi-Bing You
Jan 4, 2007·Molecular Interventions·Peter W KalivasLori Knackstedt
Nov 7, 2008·Neuroreport·Michael R TilleyHoward H Gu
Nov 11, 2008·Annals of the New York Academy of Sciences·Rajita Sinha
Aug 28, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·George F Koob, Nora D Volkow
Jun 30, 2010·Journal of Neurochemistry·Ramón Sotomayor-ZárateKatia Gysling
Sep 18, 2012·Addiction Biology·Hamid R NooriAnita C Hansson
Dec 15, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Takehiro KudoMasahiko Watanabe
Jun 15, 2013·Alcoholism, Clinical and Experimental Research·Dennis R SpartaAntonello Bonci
Aug 6, 2013·Frontiers in Psychiatry·George F Koob
Dec 10, 2013·Basic & Clinical Pharmacology & Toxicology·Ramón Sotomayor-ZárateMiguel Reyes-Parada
Jan 25, 2014·Frontiers in Neuroendocrinology·Eric P ZorrillaGeorge F Koob
May 9, 2014·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Christopher O BoysonKlaus A Miczek

❮ Previous
Next ❯

Citations

Oct 19, 2016·Molecular Pharmacology·Paula G SlaterKatia Gysling
Jan 10, 2019·Frontiers in Psychology·Angélica Torres-BerrioMauricio O Nava-Mesa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.